Organovo Holdings, Inc. (ONVO) is focused on delivering breakthrough three-dimensional biology capabilities to create tissue on demand for research and surgical applications. As the first company with a three-dimensional tissue technology that works across tissue types, they are meeting the promise of regenerative medicine to fill unmet medical needs.Organovo is an innovator in the field of 3-D printing. 3-D printers create objects and bio-medical products such as prosthetic limbs and organs on-site and on an atomic level. Such printers use computer-driven additive processes and versatile lasers or extruders moving across an X,Y, and Z axes to generate parts and products one layer at a time. In this way, products can be manufactured in whole, rather than in part, and with greater versatility and customizability. The applications of this technology to the medical industry are seemingly endless.
In an article on EnergyAndCapital.com, contributor Nathan Holl writes,
“Someday soon, quite possibly within the next couple of years, companies like Organovo will have the ability to collect stem cells from blood drawn from an adult. Then, using a specialized 3D printer, construct polymeric scaffolding in the shape of an organ or tissue needing to be replicated and literally grow a kidney, heart, or lungs within a matter of days with zero chance of rejection, circumventing the need to have patients wait for donor organs on expansive waiting lists.”
Organovo CEO Keith Murphy commented, "We currently produce organic tissues grown from cell samples, which can be used as a human analog for pharmaceutical drug discovery and development."
Read the complete article at EnergyandCapital.com.